Molecular targeted α-particle therapy for oncologic applications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25055256.
- Also identified by DOI 10.2214/AJR.14.12554 and PMC identifier 4490786.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A significant challenge facing traditional cancer therapies is their propensity to significantly harm normal tissue. The recent clinical success of targeting therapies by attaching them to antibodies that are specific to tumor-restricted biomarkers marks a new era of cancer treatments. In this article, we highlight the recent developments in α-particle therapy that have enabled investigators to exploit this highly potent form of therapy by targeting tumor-restricted molecular biomarkers.
Medical subject headings
- Alpha Particles
- Antibodies, Monoclonal
- Antineoplastic Agents
- Molecular Targeted Therapy
- Neoplasms
- Radiopharmaceuticals